Ocular Therapeutix Inc. Daily Stock Analysis

Daily Stock Analysis, OCUL, Ocular Therapeutix Inc, priceseries

Ocular Therapeutix Inc. Daily Stock Analysis
Stock Information
Open
4.93
Close
5.05
High
5.16
Low
4.93
Previous Close
4.93
Daily Price Gain
0.12
YTD High
7.38
YTD High Date
Jan 3, 2022
YTD Low
4.71
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.30
YTD Gain
-31.29%
52 Week High
21.48
52 Week High Date
Mar 15, 2021
52 Week Low
4.71
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-12.94
52 Week Gain
-71.93%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
7.18
Feb 22. 2017
8.60
8 Trading Days
19.85%
Link
LONG
Dec 8. 2017
4.15
Dec 20. 2017
4.52
8 Trading Days
9.03%
Link
LONG
Jan 11. 2018
4.91
Jan 25. 2018
5.40
9 Trading Days
9.98%
Link
LONG
Feb 23. 2018
5.04
Mar 26. 2018
6.47
21 Trading Days
28.34%
Link
LONG
Jun 5. 2018
6.86
Jun 21. 2018
7.66
12 Trading Days
11.64%
Link
LONG
Jun 26. 2019
4.27
Jul 17. 2019
4.91
14 Trading Days
14.99%
Link
LONG
Nov 21. 2019
2.95
Dec 17. 2019
3.99
17 Trading Days
35.22%
Link
LONG
Feb 3. 2020
4.52
Feb 24. 2020
5.27
14 Trading Days
16.55%
Link
LONG
Mar 3. 2020
5.46
Mar 9. 2020
5.95
4 Trading Days
8.88%
Link
LONG
Jun 12. 2020
7.45
Jun 26. 2020
8.26
10 Trading Days
10.82%
Link
LONG
Nov 19. 2020
13.74
Dec 28. 2020
20.80
25 Trading Days
51.37%
Link
Company Information
Stock Symbol
OCUL
Exchange
NasdaqGM
Company URL
http://www.ocutx.com
Company Phone
781-895-3235
CEO
Amarpreet S. Sawhney
Headquarters
Massachusetts
Business Address
15 CROSBY DRIVE, BEDFORD, MA 01730
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001393434
About

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its products include dextenza, sustained release travopost, and posterior segment injections. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical pain and inflammation, allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which is in Phase III clinical trial for glaucoma and ocular hypertension. In addition, the company has preclinical development of intravitreal depot with protein-based or small molecule drugs, including tyrosine kinase inhibitors, for the treatment of wet age-related macular degeneration and other retinal diseases. It has a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals, Inc. for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading